Xvivo Perfusion
ISIN: SE0004840718 | Ticker: XVIVO | LEI: 549300G2464FYLS14B41
Country: Sweden
XVIVO is a medical technology company with headquarter in Gothenburg, Sweden, a production site in Lund, Sweden and office in Denver, USA. We are firmly rooted in medical science and our core business is in ex vivo organ preservation. We are focused on developing optimized solutions for organ, tissue and cell preservation and perfusion in connection with transplantation. We have more than 20 years of experience within the transplant industry and are dedicated to providing more effective, clinically proven and innovative products that both increase the availability of acceptable donor organs and improve survival after transplantation.
Year founded1998
Served areaWorldwide
HeadquartersXVIVO Perfusion AB Box 53015, 40014 Göteborg – Sweden
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 1,150,309,000.00 | 1,542,596,000.00 | 1,733,084,000.00 |
| Noncurrent Assets | N/A | 687,079,000.00 | 995,064,000.00 | 1,265,576,000.00 |
| Property Plant And Equipment | N/A | 21,334,000.00 | 26,297,000.00 | 47,579,000.00 |
| Goodwill | N/A | 223,938,000.00 | 460,228,000.00 | 625,319,000.00 |
| Computer Software | N/A | 1,283,000.00 | 2,427,000.00 | 2,257,000.00 |
| Copyrights Patents And Other Industrial Property Rights Service And Operating Rights | N/A | 5,467,000.00 | 6,231,000.00 | 6,228,000.00 |
| Deferred Tax Assets | N/A | 40,334,000.00 | 42,171,000.00 | 39,272,000.00 |
| Other Noncurrent Financial Assets | N/A | 754,000.00 | 1,159,000.00 | 411,000.00 |
| Current Assets | N/A | 463,230,000.00 | 547,532,000.00 | 467,508,000.00 |
| Inventories | N/A | 59,351,000.00 | 77,590,000.00 | 106,566,000.00 |
| Current Trade Receivables | N/A | 40,183,000.00 | 52,036,000.00 | 94,500,000.00 |
| Other Current Receivables | N/A | 3,361,000.00 | 7,589,000.00 | 5,320,000.00 |
| Current Tax Assets Current | N/A | 156,000.00 | 4,286,000.00 | 4,439,000.00 |
| Cash and cash equivalents | 159,946,000.00 | 354,236,000.00 | 398,696,000.00 | 246,545,000.00 |
| Equity And Liabilities | N/A | 1,150,309,000.00 | 1,542,596,000.00 | 1,733,084,000.00 |
| Equity | 577,521,000.00 | 1,008,461,000.00 | 1,285,450,000.00 | 1,430,136,000.00 |
| Issued Capital | N/A | 734,000.00 | 754,000.00 | 762,000.00 |
| Retained Earnings | N/A | 1,125,000.00 | 9,277,000.00 | 27,753,000.00 |
| Other Reserves | N/A | -182,000.00 | 22,089,000.00 | 87,782,000.00 |
| Additional Paidin Capital | N/A | 1,006,784,000.00 | 1,253,330,000.00 | 1,313,839,000.00 |
| Liabilities | N/A | 141,848,000.00 | 257,146,000.00 | 302,948,000.00 |
| Noncurrent Liabilities | N/A | 69,600,000.00 | 152,627,000.00 | 168,052,000.00 |
| Other Longterm Provisions | N/A | 1,311,000.00 | 1,499,000.00 | 701,000.00 |
| Deferred Tax Liabilities | N/A | 24,853,000.00 | 25,084,000.00 | 25,766,000.00 |
| Other Noncurrent Liabilities | N/A | 40,150,000.00 | 124,522,000.00 | 137,130,000.00 |
| Longterm Borrowings | N/A | 3,286,000.00 | 1,522,000.00 | 4,455,000.00 |
| Current Liabilities | N/A | 72,248,000.00 | 104,519,000.00 | 134,896,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 14,468,000.00 | 21,445,000.00 | 38,469,000.00 |
| Current Accruals And Current Deferred Income Including Current Contract Liabilities | N/A | N/A | 49,970,000.00 | 55,819,000.00 |
| Current Tax Liabilities Current | N/A | 0.00 | 301,000.00 | 1,284,000.00 |
| Other Current Liabilities | N/A | 1,239,000.00 | 28,604,000.00 | 33,774,000.00 |
| Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 179,861,000.00 | 258,386,000.00 | 415,292,000.00 |
| Other Income | 1,468,000.00 | 1,249,000.00 | 4,712,000.00 |
| Profit Loss From Operating Activities | -45,675,000.00 | -18,498,000.00 | 6,409,000.00 |
| Finance Income | 890,000.00 | 45,368,000.00 | 71,598,000.00 |
| Finance Costs | 12,478,000.00 | 20,205,000.00 | 55,693,000.00 |
| Profit Loss Before Tax | -57,263,000.00 | 6,665,000.00 | 22,314,000.00 |
| Income Tax Expense Continuing Operations | -13,528,000.00 | -1,487,000.00 | 3,887,000.00 |
| Profit (loss) | -43,735,000.00 | 8,152,000.00 | 18,427,000.00 |
| Profit Loss Attributable To Owners Of Parent | -43,735,000.00 | 8,152,000.00 | 18,427,000.00 |
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -43,735,000.00 | 8,152,000.00 | 18,427,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -14,155,000.00 | -13,802,000.00 | -6,325,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -12,266,000.00 | -12,059,000.00 | 27,856,000.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 201,319,000.00 | 93,228,000.00 | 67,447,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 2,631,000.00 | 10,194,000.00 | 18,185,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 62,046,000.00 | 83,880,000.00 | 112,761,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -266,532,000.00 | -187,703,000.00 | -197,624,000.00 |
| Proceeds From Issuing Shares | N/A | 487,044,000.00 | 244,114,000.00 | -368,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 0.00 | 5,940,000.00 | 0.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 5,667,000.00 | 4,802,000.00 | 7,289,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 482,768,000.00 | 234,611,000.00 | -6,842,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 203,970,000.00 | 34,849,000.00 | -176,610,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -9,680,000.00 | 9,611,000.00 | 24,459,000.00 |
| Cash and cash equivalents | 159,946,000.00 | 354,236,000.00 | 398,696,000.00 | 246,545,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 29.02.24 | Kristoffer Nordström | Other | Buy | SEK 88,440.00 |
| 14.11.23 | Gösta Johannesson | Other | Buy | SEK 124,500.00 |
| 24.04.23 | Lars Henriksson | Other | Buy | SEK 107,200.00 |
| 02.11.22 | Gösta Johannesson | Other | Buy | SEK 34,000.00 |
| 01.11.22 | Gösta Johannesson | Other | Buy | SEK 166,500.00 |
| 19.08.22 | Dag Andersson Tilk | Other | Buy | SEK 99,700.20 |
| 24.05.22 | Dag Andersson Tilk | Other | Other | SEK 1,115,251.96 |
| 24.05.22 | Christoffer Björn Rosenblad | Other | Other | SEK 557,523.04 |
| 24.05.22 | Kristoffer Nordström | Other | Other | SEK 278,761.52 |
| 20.05.22 | Dag Andersson Tilk | Other | Buy | SEK 33,986.25 |
| Position Holder | Short Interest in Percent | Date |
|---|---|---|
| JPMorgan Asset Management (UK) Ltd | 0.71% | 19.02.24 |
| Total | 0.71% |
SE0004840718
LEI549300G2464FYLS14B41
SectorHealth Care Equipment & Services
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.